Chronic Kidney Disease
Conditions
Keywords
Chronic kidney disease
Brief summary
Randomized controlled double blind study of parallel groups to evaluate the comparative effects of low-dose of atorvastatin on proteinuria in patients with stage 3 or 4 chronic kidney disease.
Interventions
DRUGAtorvastatin
Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
Sponsors
Laval University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age of 18 and over * Stage 3 or 4 chronic kidney disease (modified MDRD) * proteinuria of \> 1g/d on ACEi and/or ARB, or proteinuria of \> 1g/d with intolerance or contraindication to ACEi and/or ARB * blood pressure \< 130/80 mmHg or \< 140/90 mmHg in patients with five or more antihypertensive drugs * stable renal function
Exclusion criteria
* rapid progression of renal failure * immunosuppressive therapy within the past 3 months * need a renal replacement therapy within 8 months * definite history of chronic liver disease, or abnormal liver function * evidence of active inflammatory muscle disease * definite previous adverse reaction to a statin * concurrent treatment with a contraindicated drug (fibrate, macrolide antibiotic, systemic use of imidazole or triazole antifungals, protease-inhibitors, ciclosporin) * child bearing potential * known to be poorly compliant with clinic visits or prescribed medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proteinuria | 6 months |
Countries
Canada
Outcome results
None listed